A5066914100- Radiopharmaceutical Chemistry and Applications
- Intraperitoneal and Appendiceal Malignancies
- Neuroendocrine Tumor Research Advances
- Hepatocellular Carcinoma Treatment and Prognosis
- Monoclonal and Polyclonal Antibodies Research
- Hormonal Regulation and Hypertension
- Ovarian cancer diagnosis and treatment
- CAR-T cell therapy research
- Chemical Synthesis and Analysis
- Viral Infectious Diseases and Gene Expression in Insects
- Peptidase Inhibition and Analysis
- Renal and related cancers
- Pancreatic and Hepatic Oncology Research
- HER2/EGFR in Cancer Research
- Prostate Cancer Treatment and Research
- Cancer Cells and Metastasis
- Virus-based gene therapy research
- ATP Synthase and ATPases Research
- Cancer, Hypoxia, and Metabolism
- Medical Imaging Techniques and Applications
- Lung Cancer Research Studies
- Radiomics and Machine Learning in Medical Imaging
- Medical Imaging and Pathology Studies
- Glycosylation and Glycoproteins Research
National Cancer Institute
2020-2023
National Institutes of Health
2020-2023
Memorial Sloan Kettering Cancer Center
2018-2023
Center for Cancer Research
2022
Binghamton University
2016
Neuroendocrine tumors (NETs) express somatostatin receptors (SSTRs) 2 and 5. Modified variants of somatostatin, the cognate ligand for SSTR2 SSTR5, are used in treatment metastatic locoregional disease. Peptide receptor radionuclide therapy with <sup>177</sup>Lu-DOTATATE (DOTA-octreotate), a β-particle–emitting derivative, has demonstrated survival benefit patients SSTR-positive NETs. Despite excellent results, subset that resistant to treatment, alternative agents needed. Targeted...
There remains an urgent need for the noninvasive tracking of transfused chimeric antigen receptor (CAR) T cells to determine their biodistribution, viability, expansion, and antitumor functionality. DOTA antibody reporter 1 (DAbR1) comprises a single-chain fragment antilanthanoid-DOTA 2D12.5/G54C fused human CD4-transmembrane domain binds irreversibly lanthanoid (<i>S</i>)-2-(4-acrylamidobenzyl)-DOTA (AABD). The aim this study was investigate whether DAbR1 can be expressed on lymphocytes...
This is the initial report of an α-based pre-targeted radioimmunotherapy (PRIT) using 225Ac and its theranostic pair, 111In. We call our novel tumor-targeting DOTA-hapten PRIT system "proteus-DOTA" or "Pr." Herein we first results radiochemistry development, radiopharmacology, stoichiometry tumor antigen binding, including role specific activity, anti-tumor efficacy, normal tissue toxicity with Pr-PRIT approach (as α-DOTA-PRIT). A series α-DOTA-PRIT therapy studies were performed in three...
Glypican-3 (GPC3) is expressed in 75% of hepatocellular carcinoma (HCC), but not normal liver, making it a promising HCC therapeutic target. GC33 full-length humanized monoclonal IgG1 specific to GPC3 that can localize vivo. alone failed demonstrate efficacy when evaluated patients with HCC; however, we posit cytotoxic functionalization the antibody radionuclides, may be warranted. Alpha particles, which are emitted by radioisotopes such as Actinium-225 (Ac-225) exhibit high linear energy...
In recent reports, we have shown that optimized pretargeted radioimmunotherapy (PRIT) based on molecularly engineered antibody conjugates and 177 Lu-DOTA chelate (DOTA-PRIT) can be used to cure mice bearing human solid tumor xenografts using antitumor antibodies minimally internalizing membrane antigens, GPA33 (colon) GD2 (neuroblastoma).However, many antigens are internalized after binding it is generally believed not suitable targets for PRIT.In this study, tested the hypothesis DOTA-PRIT...
Peritoneal carcinomatosis (PC) is considered incurable, and more effective therapies are needed. Herein we test the hypothesis that GPA33-directed intracompartmental pretargeted radioimmunotherapy (PRIT) can cure colorectal peritoneal carcinomatosis. Nude mice were implanted intraperitoneally with luciferase-transduced GPA33-expressing SW1222 cells for aggressive (e.g., resected tumor mass 0.369 ± 0.246 g;
Purpose: TRA-1-60 (TRA) is an established transcription factor of embryonic signaling and a well-known marker pluripotency.It has been implicated in tumorigenesis metastases, not expressed differentiated cells, which makes it appealing biomarker for immunopositron emission tomography (immunoPET) imaging radiopharmaceutical therapy (RPT).Herein, we explored the clinical implications TRA prostate cancer (PCa), examined potential TRA-targeted PET to specifically image + stem cells (CSCs)...
Background Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. While conventional imaging approaches like ultrasound, CT, and MRI play critical roles in diagnosis surveillance of HCC, improved methods for detection assessment treatment response are needed. One promising approach use radiolabeled antibodies positron emission tomography (immunoPET) imaging. Glypican-3 (GPC3) a proteoglycan that highly expressed majority HCC tumors. GPC3-specific used to diagnose...
<div>Abstract<p>Peritoneal carcinomatosis (PC) is considered incurable, and more effective therapies are needed. Herein we test the hypothesis that GPA33-directed intracompartmental pretargeted radioimmunotherapy (PRIT) can cure colorectal peritoneal carcinomatosis. Nude mice were implanted intraperitoneally with luciferase-transduced GPA33-expressing SW1222 cells for aggressive (e.g., resected tumor mass 0.369 ± 0.246 g; <i>n</i> = 17 on day 29). For GPA33-PRIT,...
<p>Supplementary Data</p>
<p>Supplementary Data</p>
<div>Abstract<p>Peritoneal carcinomatosis (PC) is considered incurable, and more effective therapies are needed. Herein we test the hypothesis that GPA33-directed intracompartmental pretargeted radioimmunotherapy (PRIT) can cure colorectal peritoneal carcinomatosis. Nude mice were implanted intraperitoneally with luciferase-transduced GPA33-expressing SW1222 cells for aggressive (e.g., resected tumor mass 0.369 ± 0.246 g; <i>n</i> = 17 on day 29). For GPA33-PRIT,...